Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | BTN3A1 | O00481 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28841738 | 1.00 | ALDH1A1 (0.48) | ALDH1A1CA1CA2CES2CES1 | |
| SCHEMBL15343943 | 1.00 | ALDH1A1 (0.48) | ALDH1A1CA1CA2CES2CES1 | |
| SCHEMBL15343942 | 1.00 | ALDH1A1 (0.48) | ALDH1A1CA1CA2CES2CES1 | |
| SCHEMBL18742082 | 0.96 | CA1 (0.51) | ALDH1A1CA1CA2CES2CES1 | |
| SCHEMBL30497665 | 0.91 | ALDH1A1 (0.49) | ALDH1A1CA1CA2CES2CES1 | |
| SCHEMBL15588696 | 0.90 | BTN3A1 (0.48) | ALDH1A1CA1CA2CES2CES1 | |
| SCHEMBL851091 | 0.90 | BTN3A1 (0.48) | ALDH1A1CA1CA2CES2CES1 | |
| SCHEMBL851467 | 0.90 | BTN3A1 (0.48) | ALDH1A1CA1CA2CES2CES1 | |
| SCHEMBL850882 | 0.90 | BTN3A1 (0.48) | ALDH1A1CA1CA2CES2CES1 | |
| SCHEMBL13051654 | 0.90 | BTN3A1 (0.48) | ALDH1A1CA1CA2CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109724-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4107164-B1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-12-03 | — | — | EP | disclosed |
| US-12264173-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| CN-115175735-B | Antiviral compounds | 吉利德科学公司 | 2025-03-04 | — | — | CN | disclosed |
| US-20240174704-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2024-05-30 | — | — | US | disclosed |
| US-20230382931-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2023-11-30 | — | — | US | disclosed |
| US-20230382931-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2023-11-30 | — | — | US | disclosed |
| US-11767337-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767337-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767337-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20220356196-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2022-11-10 | — | — | US | disclosed |
| US-20210284670-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2021-09-16 | — | — | US | disclosed |
| US-20210054008-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2021-02-25 | — | — | US | disclosed |
| US-10822360-B2 | Dioxolane analogues of uridine for the treatment of cancer | MEDIVIR AB (SE) | 2020-11-03 | — | — | US | disclosed |
| US-20200239502-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2020-07-30 | — | — | US | disclosed |
| US-10654877-B2 | Dioxolane analogues of uridine for the treatment of cancer | MEDIVIR AB (SE) | 2020-05-19 | — | — | US | disclosed |
| US-10336780-B2 | Dioxolane analogues of uridine for the treatment of cancer | MEDIVIR AB (SE) | 2019-07-02 | — | — | US | disclosed |
| US-20190100541-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2019-04-04 | — | — | US | disclosed |
| US-20170267705-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2017-09-21 | — | — | US | disclosed |
| US-20170267705-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2017-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220356196-A1 | ANTIVIRAL COMPOUNDS | MAVS, HAVCR2, ZC3HAV1 | ALDH1A1 1459/4885CA1 4866/4885CA2 4718/4885 |
| US-20200239502-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NTPCR | ALDH1A1 382/4885CA1 4799/4885CA2 4866/4885 |
| US-20260109724-A1 | ANTIVIRAL COMPOUNDS | IRF3, IFNAR1, HAVCR2 | ALDH1A1 744/4885CA1 4447/4885CA2 3731/4885 |
| US-20210284670-A1 | ANTIVIRAL COMPOUNDS | MAVS, HAVCR2, ZC3HAV1 | ALDH1A1 1459/4885CA1 4866/4885CA2 4718/4885 |
| US-12264173-B2 | Antiviral compounds | MAVS, HAVCR2, ZC3HAV1 | ALDH1A1 1459/4885CA1 4866/4885CA2 4718/4885 |
| US-11767337-B2 | Antiviral compounds | MAVS, HAVCR2, ZC3HAV1 | ALDH1A1 1459/4885CA1 4866/4885CA2 4718/4885 |
| US-20240174704-A1 | ANTIVIRAL COMPOUNDS | MAVS, HAVCR2, ZC3HAV1 | ALDH1A1 1459/4885CA1 4866/4885CA2 4718/4885 |
| US-20190100541-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NT5C | ALDH1A1 391/4885CA1 4788/4885CA2 4859/4885 |
| US-20170267705-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, NT5C, DUT | ALDH1A1 631/4885CA1 4800/4885CA2 4873/4885 |
| US-10654877-B2 | Dioxolane analogues of uridine for the treatment of cancer | ADORA3, DUT, NTPCR | ALDH1A1 382/4885CA1 4799/4885CA2 4866/4885 |
| US-10336780-B2 | Dioxolane analogues of uridine for the treatment of cancer | ADORA3, DUT, NT5C | ALDH1A1 409/4885CA1 4780/4885CA2 4861/4885 |
| US-20210054008-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NTPCR | ALDH1A1 382/4885CA1 4799/4885CA2 4866/4885 |
| US-20230382931-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NTPCR | ALDH1A1 382/4885CA1 4799/4885CA2 4866/4885 |
| US-10822360-B2 | Dioxolane analogues of uridine for the treatment of cancer | ADORA3, DUT, NTPCR | ALDH1A1 382/4885CA1 4799/4885CA2 4866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.